Topical Stem Cell Serum Reverses Skin Aging by Rebooting Cellular Housekeeping

News
#1

SecretomeSkinTopoical
SecretomeSkinTopoical2752×1536 419 KB

Chronic exposure to ultraviolet radiation damages cellular power plants, known as mitochondria, causing them to leak genetic material into the cell interior and ignite severe tissue inflammation. Researchers have demonstrated that a non-invasive, topically applied liquid formulation containing the regenerative secretome of human umbilical cord stem cells reverses photoaging in sun-damaged skin. By reactivating mitophagy, the intracellular housekeeping mechanism that isolates and digests damaged organelles, this surface-applied therapy prevents mitochondrial DNA leakage and silences the inflammatory cGAS-STING alarm cascade, restoring skin hydration, elasticity, and dermal collagen architecture without requiring cellular injections.

Chronic solar exposure takes an undeniable toll on human skin, accelerating wrinkle formation, loss of structural elasticity, and barrier breakdown. While dermatologists have long relied on conventional topical treatments containing retinoids or antioxidants, these options frequently cause erythema and peeling or suffer from poor stability and limited tissue absorption. Now, researchers at Southern Medical University have demonstrated that a topical formulation containing the regenerative secretome of human umbilical cord mesenchymal stem cells can reverse established photoaging at the molecular level.

The therapy sidesteps the safety concerns, ethical controversies, and delivery hurdles associated with injecting living cells. Instead, the researchers developed a cell-free topical liquid preparation composed of the complete broth of signaling proteins, growth factors, and extracellular vesicles harvested from stem cell cultures. Applied daily as a surface treatment directly to ultraviolet-damaged skin, this topical cocktail delivered a restorative signal that penetrated the cutaneous barrier to rescue stressed epidermal cells.

At the center of this discovery is how the surface-applied formula restores mitochondrial housekeeping. Ultraviolet radiation severely damages mitochondria, the energy-producing powerhouses within skin cells. Healthy skin relies on a specialized recycling process called mitophagy to detect and dismantle these failing organelles. Chronic ultraviolet exposure paralyzes this clearance machinery. Deprived of proper cellular disposal, swollen and ruptured mitochondria leak fragments of their internal genetic material directly into the cellular interior.

Floating freely inside the cytoplasm, this misplaced mitochondrial DNA triggers a primitive immune alarm known as the cGAS-STING pathway. Misinterpreting internal mitochondrial leakage as an invading viral pathogen, this pathway unleashes a damaging cascade of inflammatory cytokines like interleukin-6 and interferon-beta, degrading the structural dermal scaffold and locking skin cells into permanent, non-dividing senescence.

Daily topical application of the stem cell secretome completely halted this destructive cascade. The topically delivered factors restored the expression of critical regulatory proteins, PINK1 and Parkin, re-establishing efficient autophagic disposal of crippled mitochondria. By clearing the structural debris before mitochondrial DNA could escape into the cytoplasm, the topical treatment silenced the cGAS-STING alarm system at its root.

The physiological turnaround was dramatic. The topical formula eliminated abnormal epidermal thickening, restored skin hydration and elasticity back to youthful baseline values, and halted the activation of matrix metalloproteinases that chew through dermal collagen. Notably, the surface application also suppressed circulating inflammatory markers throughout the bloodstream, demonstrating that treating the skin barrier topically dampens broader systemic inflammation. By proving that a surface-applied formulation can reboot intracellular organelle quality control and extinguish sterile tissue inflammation, this study points toward a new class of non-invasive, cell-free biologic treatments for environmental photoaging.

Actionable Insights

This study reveals that clearing damaged mitochondria and blocking the cytosolic DNA-sensing cascade are vital requirements for reversing sun-induced tissue aging. For individuals seeking practical longevity takeaways, the findings indicate that topical mesenchymal stem cell secretomes and condition-matched extracellular vesicles represent a promising cell-free therapeutic class.

The measured real-world magnitude of this topical intervention is exceptionally large. In animal models subjected to chronic ultraviolet exposure, topical secretome application reduced transepidermal water loss by 59.6 percent, reflecting an absolute reduction of 27.7 grams per square meter per hour and a standardized effect size of approximately d = 9.1, fully restoring the epidermal moisture barrier. Epidermal hydration improved by 78.4 percent, an absolute recovery of 21.0 arbitrary units (d ≈ 4.9), while skin elasticity gained 21.0 percentage points, an improvement of 57.5 percent (d ≈ 4.2). At the tissue architecture level, abnormal epidermal thickening was reduced by 64.2 percent (d ≈ 6.7).

While over-the-counter stem cell conditioned media products remain variable in potency, these data demonstrate that interventions designed to stimulate mitophagy or limit mitochondrial oxidative leakage can fundamentally alter cutaneous senescence trajectories.

Source / Context:

  • Open Access Paper: The Secretome Derived From Human Umbilical Cord Mesenchymal Stem Cells Improves Skin Photoaging by Enhancing Mitophagy to Inhibit the cGAS-STING Pathway
  • Institutions: Department of Histology and Embryology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Department of Pathology, Wuping County Hospital, Longyan, China; School of Public Health, Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, China; SNMPA Center for Innovation and Research in Regulatory Science, Guangzhou, China; Key Laboratory of Functional Proteomics of Guangdong Province, School of Basic Medical Sciences, Southern Medical University, Guangzhou.
  • Country: China
  • Journal Name: Aging Cell
  • Impact Evaluation: The impact score of this journal is 7.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.
1 Like
How to Stop or Reverse Skin Aging (2026)
#2

This seems like it could be a very big development in the skin aging / cosmetic dermatology field. The effect sizes (how well it improves things) are very significant. And, importantly, it’s a topical application (e.g. cream or serum), not an injectable solution, so much easier to use for people. However, as a biologic its going to likely be difficult to manufacture, and expensive to produce and distribute.

SkinBarCht
SkinBarCht2752×1536 151 KB

Novelty

Prior investigations have shown that mesenchymal stem cell secretomes possess regenerative and anti-inflammatory properties, frequently attributing these effects to vague antioxidant mechanisms or general STAT3 modulation. Furthermore, studies in neurodegeneration and cardiomyopathy have previously connected mitophagy to cGAS-STING suppression.

This study introduces two definitive advancements:

  1. It provides in vivo and in vitro proof that the human umbilical cord mesenchymal stem cell secretome directly rescues cutaneous photoaging by restoring the PINK1/Parkin-mediated mitophagy pathway.

  2. Through dual-pharmacological epistasis using Mdivi-1 and H151, it confirms that STING activation is the mandatory downstream pathway through which defective mitochondrial quality control triggers cellular senescence and barrier collapse in skin.

Quantitative Summary of Physiological and Molecular Biomarker Responses

Biomarker / Parameter Control Baseline (Unirradiated) UV Damage Model (Untreated Control) UV + Topical SCT (Treated Group) Net Absolute Change Percent Improvement (vs. UV Model) Standardized Effect Size (Cohen’s d)
Transepidermal Water Loss (TEWL) 22.0 ± 2.5 g/(mÂČ·h) 46.5 ± 3.5 g/(mÂČ·h) 18.8 ± 2.5 g/(mÂČ·h) -27.7 g/(mÂČ·h) 59.6% reduction (100.0% normalization to baseline) d ≈ 9.1 (Extremely Large)
Stratum Corneum Hydration 54.5 ± 5.0 a.u. 26.8 ± 4.0 a.u. 47.8 ± 4.5 a.u. +21.0 a.u. 78.4% increase (87.7% recovery of baseline hydration) d ≈ 4.9 (Extremely Large)
Cutaneous Elasticity 54.0 ± 6.0% 36.5 ± 5.0% 57.5 ± 5.0% +21.0% points 57.5% increase (106.5% of non-irradiated baseline) d ≈ 4.2 (Extremely Large)
Epidermal Thickness (Hyperplasia) 18.0 ± 4.0 ”m 53.0 ± 6.0 ”m 19.0 ± 4.0 ”m -34.0 ”m 64.2% reduction (97.1% recovery toward normal thickness) d ≈ 6.7 (Extremely Large)
Dermal Thickness (Edema / Fibrosis) 100.0 ± 15.0 ”m 305.0 ± 25.0 ”m 135.0 ± 20.0 ”m -170.0 ”m 55.7% reduction (82.9% resolution of swelling/fibrosis) d ≈ 7.5 (Extremely Large)
Serum Interleukin-6 (IL-6) 1.1 ± 0.2 pg/mL 5.5 ± 0.6 pg/mL 1.0 ± 0.1 pg/mL -4.5 pg/mL 81.8% reduction (100.0% normalization to baseline) d ≈ 10.5 (Extremely Large)
Serum Interferon-beta (IFN-ÎČ) 0.7 ± 0.1 pg/mL 4.0 ± 0.4 pg/mL 0.7 ± 0.1 pg/mL -3.3 pg/mL 82.5% reduction (100.0% normalization to baseline) d ≈ 11.4 (Extremely Large)
Keratinocyte Proliferation (EdU) 100.0% 50.0% of baseline 91.0% of baseline +41.0% points 82.0% increase (reaches 91.0% of undamaged capacity) d ≈ 3.8 (Extremely Large)
Keratinocyte Senescence (SA-ÎČ-gal) Unirradiated baseline >120% induction ~34% positive cells -86.0% points 72.0% reduction in senescent cell burden N/A (Non-parametric index)
1 Like
#3

My effort at looking into any possible commercialization efforts related to this research (via Claude Opus 5 Extra):

Short answer

No commercialization traceable to this group or this specific paper. The broader line of research, topical MSC-derived secretome for skin aging, is one of the most heavily commercialized areas in aesthetics worldwide, but almost entirely outside a regulatory framework that would require efficacy evidence. Human clinical evaluation exists, is modest in size and quality, and has never tested the product or the mechanism described here.

What the paper itself discloses

The paper declares no conflicts of interest. Funding is entirely public: National Natural Science Foundation of China grants 82073417, 81703147 and 81402613, plus Guangdong Basic and Applied Basic Research Foundation grant 2022A1515010768. No company supplied the secretome. It was produced in house from a single donor’s Wharton’s jelly, passage 5, 72 hours in serum-free medium, 2.548 mg/mL total protein, with pooling of donors explicitly avoided.

Two signals are worth noting anyway.

The Southern Medical University group sits inside China’s cosmetics regulatory apparatus. Affiliation 5 on this paper is the NMPA Center for Innovation and Research in Regulatory Science. Their companion paper on the same secretome platform for hair growth (Stem Cell Research and Therapy, 2025, full text) lists an NMPA Key Laboratory for Safety Evaluation of Cosmetics affiliation alongside a Nanfang Hospital plastic and aesthetic surgery co-affiliation. That is a lab positioned at the science-to-regulation interface, not a lab with a spinout (confidence 0.8).

They are building a platform rather than a one-off result. Skin photoaging plus hair growth from the same conditioned medium preparation is the usual pattern preceding IP filing. I found no patent under these inventors’ names. The surrounding IP space is already crowded with unrelated filings on the same material, for example CN116987151A, granted in February 2024 to Shaanxi Zhonggang Wanhai Life Science Research Institute, covering umbilical cord MSC supernatant in skin repair and anti-aging skincare. Caveat on my search: CNIPA filings are poorly indexed by English-language search and carry an 18-month publication delay, so a 2025 or 2026 filing from this group would not yet be visible. Confidence that no public patent exists today is 0.85; confidence that none has been filed is 0.5.

Commercialization of the same approach

China

Mainland China is the one place this cannot legally become a cosmetic. The 2015 Safety and Technical Standards for Cosmetics prohibit human cells, tissues and human-origin products as cosmetic ingredients, and NMPA has not approved exosomes as a cosmetic ingredient, as summarized in CIRS Group’s jurisdiction-by-jurisdiction analysis and in ZMUni’s compilation of global requirements for human-derived exosomes. CDE has separately been folding exosome products into the cell therapy regulatory framework. The practical result is that a topical hUC-MSC secretome carrying anti-aging claims has no clean domestic route: too human-derived to be a cosmetic, too poorly characterized to be a straightforward biologic.

The workaround is to commercialize offshore. Beijing Guowei Biotechnology obtained an INCI listing for “Human Umbilical Wharton’s Jelly Mesenchymal Stem Cell Exosomes,” which is the identical starting tissue to this paper. That listing opens the US, EU, Japan and Korea, and explicitly not China. It is the closest commercial analogue to this paper’s material that I could identify, with the caveat that the paper uses whole secretome rather than purified exosomes, so it is a tissue-source match and not a product match (confidence 0.9 on the tissue-source match).

China’s domestic exosome sector is real but mostly pharmaceutical rather than dermatological. An industry census of roughly 49 Chinese exosome companies names Enze Kangtai, Bailai Regenerative Medicine and Bailian Pharmaceuticals, none of them positioned in skin aging. Meanwhile Chinese medical aesthetics clinics sell stem cell supernatant facials in a substantial gray market with no ingredient approval behind it.

South Korea

The most productized market. ExoCoBio’s ASCE+ line of adipose-derived stem cell exosomes is the category leader; the company received MFDS GMP licensing for exosome biopharmaceuticals in 2023 and that same year completed its acquisition of the US aesthetic brand BENEV. Korea permits human cell and tissue culture fluid in cosmetics under Article 8, Appendix 3 of its Cosmetics Act.

Korea also shows what happens when a category outruns its evidence. In January 2025 MFDS expanded the list of prohibited cosmetic advertising expressions to bar the word exosome unless the ingredient is plant or animal derived, bar hospital-exclusive framing, and bar quantitative anti-aging claims. By May 2025, inspections had logged 237 online advertising violations, with roughly 48 percent judged to read as drug or medical claims.

Japan

Clinic-sold human stem cell culture supernatant is permitted under Japan’s Guidelines for Biological-Derived Materials, with source controls and strict advertising limits, again per the CIRS analysis. Clinics market it directly to consumers as drip, injection or topical treatment, as at Elm Clinic and Setagaya Clinic. This is the closest real-world match anywhere to the paper’s actual material, an undefined conditioned medium applied to skin, sold at scale. Permission here reflects a materials-safety category, not any efficacy assessment.

United States

Most permissive for topical use, most restrictive for injection. The INCI database lists 59 exosome ingredients, mostly plant derived, and human MSC exosome topicals sell as cosmetics. Elevai Skincare is a publicly traded example that has run its own small studies, launching one in October 2024 and announcing positive results on completion. Company-sponsored, unregistered, and not peer reviewed, so weight accordingly.

Injectable exosomes are unapproved biologics. FDA issued a public safety notification on exosome products and a public safety alert on unapproved stem cell and exosome marketing after patient hospitalizations. Enforcement has continued through the Kimera Labs warning letter in September 2023, Supreme Rejuvenation in May 2025, and Dynamic Stem Cell Therapy in February 2026.

Southeast Asia

Indonesia and Thailand have active secretome clinic markets and, tellingly, contribute a disproportionate share of the published clinical trials in this area. Indonesian dermatology reviews treat secretome as a standard clinical option in a way no Western review does.

Clinical evaluations

Nothing has tested this paper’s product or its mechanism in humans. No trial has used single-donor, serum-free hUC-MSC whole secretome topically for UV photoaging, and no human study has evaluated mitophagy restoration or cGAS-STING suppression in skin as a readout (confidence 0.95).

What does exist, in descending order of relevance to this paper:

Closest cell source and delivery match. Efficacy of Microneedling Combined With Local Application of Human Umbilical Cord-Derived MSC Conditioned Media in Skin Brightness and Rejuvenation, a randomized controlled split-face study in Frontiers in Medicine (2022, PubMed). Same tissue source and same unfractionated conditioned medium, but delivered through microneedling channels rather than across intact skin, which is a materially different pharmacokinetic situation.

Pooled evidence. Effectiveness of Topical Conditioned Medium of Stem Cells in Facial Skin Nonsurgical Resurfacing Modalities for Antiaging, a systematic review and meta-analysis in Aesthetic Plastic Surgery (2023, PubMed), identified five RCTs and pooled four. It reported improvement in wrinkles, pigmentation, pores and overall skin condition, at Level of Evidence III. Two structural problems limit what you can take from it. The conditioned medium is always an adjunct to a resurfacing procedure that is independently effective, so the increment attributable to the secretome is not separable. And it reports p values rather than standardized effect sizes, so the practical magnitude of benefit cannot be recovered from the paper. A published commentary in the same journal argued explicitly that further studies are needed before these conclusions hold.

Umbilical cord source, individual trials:

Adipose source, for comparison, since the adipose literature is deeper:

China specifically. The registered trial closest to this work is NCT06677931 at Fujian Medical University Union Hospital: umbilical cord MSC-derived exosomes delivered with a 1565 nm non-ablative fractional laser for melasma, n=30, completed, listing details here. Pigmentation rather than photoaging, and a different institution from this paper’s group.

Certainty of the whole body of evidence. A 2026 systematic review applying GRADE rated certainty as low for elasticity, collagen synthesis and wrinkle reduction, and moderate for safety. Across 347 participants with detailed adverse event reporting, 98.4 percent of events were grade 1 and self-limiting within 24 to 72 hours, with no tumorigenicity signal out to five years. That review also tabulates two studies I could not retrieve as primary sources and am therefore citing at second hand: Estupiñan et al. 2025 (US, adipose exosomes intradermal versus PRP, split-face non-inferiority RCT, n=20, roughly 31 percent elasticity and 24 percent wrinkle improvement) and Ponnikorn et al. 2026 (Thailand, umbilical cord versus adipose exosomes intradermal, prospective cohort, n=120, five-year follow-up). The Thai study is the largest and longest dataset in the field but is a cohort, not randomized, so it cannot separate treatment effect from selection.

In plain terms: the safety picture is reasonably reassuring, the efficacy picture is not yet trustworthy, because the studies are small, short, mostly split-face, mostly adjunctive, and the product differs in every single one. A 2024 review of the same literature reaches the same conclusion from a different angle.

Two gaps worth flagging for your readers

Dose. The mice in this study received 200 uL of undiluted stock daily onto a 2.5 by 1.5 cm field, which works out to about 136 micrograms of secretome protein per square centimeter per day, for 30 consecutive days, on skin with a thinner barrier than human facial skin. Commercial topicals essentially never disclose secretome protein content, so the comparison cannot be completed, but the mouse exposure is almost certainly far above what any consumer serum delivers (confidence 0.85). The paper’s disclosure of a 2.548 mg/mL stock concentration is itself more transparency than the commercial category offers.

Product identity. The paper’s material is deliberately single-donor, unpooled, serum-free and unfractionated. Commercial products are typically pooled across donors, exosome-enriched or lyophilized, and reconstituted. The preclinical result therefore does not transfer to anything currently on sale, even where the cell source matches exactly, as with the Guowei Wharton’s jelly exosome ingredient.

The mechanism claim, mitophagy restoration suppressing cGAS-STING-driven inflammaging, is scientifically the most interesting part and the least commercialized. Small-molecule STING inhibition for inflammaging is an active drug development thread, but nobody is selling a secretome on a STING-suppression rationale (confidence 0.9). If this group files IP, that axis is the plausible claim.

2 Likes
#4

More on the Commercialization of “Human Umbilical Wharton’s Jelly Mesenchymal Stem Cell Exosomes,”

Commercial applications exist today, but severe global regulatory barriers restrict their widespread use.

The ingredient referenced in the REACH24H press release is Human Umbilical Wharton’s Jelly Mesenchymal Stem Cell Exosomes (INCI Monograph ID: 39100). While the International Nomenclature of Cosmetic Ingredients (INCI) designation was successfully acquired, it must be clarified that an INCI name is merely a universally recognized cataloging identifier. It does not confer regulatory approval, safety validation, or legal market access in any specific jurisdiction.

Current Commercial Applications

Commercialization of human-derived cosmetic exosomes is currently isolated to specific regional markets with bespoke regulatory pathways for biologicals in cosmetics, most notably Taiwan.

  • Marketed Products: A Taiwanese biotechnology company, ExoOne Bio Co., Ltd., secured approval from the Taiwan Food and Drug Administration (TFDA) in April 2024 to utilize human umbilical cord mesenchymal stem cell (UCMSC) exosomes in cosmetic formulations.
  • Specific Formulations: Commercial products utilizing this specific biotechnology currently include ExoOne Hair Essence, ExoMuse Ampule, and ExoMuse Essence. These are marketed primarily for regenerative aesthetics and hair restoration.

Global Regulatory Restrictions

Despite the INCI listing, the commercial viability of this product in major global markets faces stringent prohibitions. Human-derived exosomes are not universally legally compliant as over-the-counter cosmetic ingredients.

  • United States: The FDA strictly classifies any topical exosome product making structure-or-function claims (e.g., “regenerates skin,” “stimulates collagen”) as an unapproved drug or biologic. As of 2026, zero exosome products have received FDA approval for aesthetic or cosmetic use. The FDA has issued multiple warning letters explicitly stating that marketing or administering unapproved human-derived exosome products violates federal law.
  • European Union: The product is explicitly banned for cosmetic use. EU Regulation (EC) No. 1223/2009, Annex II/416 strictly prohibits “cells, tissues or products of human origin” from being used in cosmetic formulations.
  • China: Formulations utilizing human-derived cells or their byproducts generally face a ban in consumer cosmetics, requiring an arduous pathway via drug or medical device regulatory frameworks rather than standard cosmetic notifications.

Knowledge Gaps and Efficacy Concerns

From a biological aging perspective, while human UCMSC-derived exosomes possess potent signaling molecules (e.g., miRNAs, growth factors) for modulating extracellular matrix production or cellular repair in vitro, their in vivo topical efficacy is the subject of ongoing scholarly debate.

The primary knowledge gap is dermatological penetration kinetics. The extent to which 20–200 nanometer lipid vesicles can bypass an intact stratum corneum to reach target dermal fibroblasts without mechanical disruption (such as clinical microneedling) remains unverified. Furthermore, requiring mechanical disruption immediately blurs the regulatory line between a topical cosmetic application and a medical procedure. Robust, independent clinical data detailing long-term safety, viral clearance validation, and precise transdermal delivery mechanisms are required before their anti-aging efficacy can be considered a verified fact.

1 Like